Patents Assigned to EMD Lexigen Research Center Corp.
-
Patent number: 7833976Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.Type: GrantFiled: April 21, 2008Date of Patent: November 16, 2010Assignees: The Scripps Research Institute, EMD Lexigen Research Center Corp.Inventors: Holger N. Lode, Ralph A. Reisfeld, David A. Cheresh, Stephen D. Gillies
-
Publication number: 20080311655Abstract: Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.Type: ApplicationFiled: May 21, 2007Publication date: December 18, 2008Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo, Yan Lan
-
Patent number: 7365054Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.Type: GrantFiled: September 26, 2006Date of Patent: April 29, 2008Assignees: The Scripps Research Institute, EMD Lexigen Research Center Corp.Inventors: Holger N. Lode, Ralph A. Reisfeld, David A. Cheresh, Stephen D. Gillies
-
Patent number: 7323549Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).Type: GrantFiled: December 30, 2004Date of Patent: January 29, 2008Assignee: EMD Lexigen Research Center Corp.Inventors: Scott Lauder, Stephen D. Gillies
-
Publication number: 20070258944Abstract: The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein complexes and fusion proteins are also disclosed.Type: ApplicationFiled: November 20, 2006Publication date: November 8, 2007Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Kin-Ming Lo
-
Patent number: 7226998Abstract: Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.Type: GrantFiled: September 7, 2004Date of Patent: June 5, 2007Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo, Yan Lan
-
Publication number: 20070059282Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.Type: ApplicationFiled: November 15, 2006Publication date: March 15, 2007Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Kin-Ming Lo, Susan Qian
-
Patent number: 7186804Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.Type: GrantFiled: December 4, 2002Date of Patent: March 6, 2007Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Pascal A. Stein, Kin-Ming Lo
-
Publication number: 20070036752Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.Type: ApplicationFiled: October 16, 2006Publication date: February 15, 2007Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Pascal Stein, Kin-Ming Lo
-
Patent number: 7169904Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.Type: GrantFiled: December 16, 2003Date of Patent: January 30, 2007Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo, Susan X. Qian
-
Patent number: 7148321Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.Type: GrantFiled: March 7, 2002Date of Patent: December 12, 2006Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo
-
Patent number: 7141651Abstract: The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein complexes and fusion proteins are also disclosed.Type: GrantFiled: June 24, 2003Date of Patent: November 28, 2006Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo
-
Publication number: 20060263856Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.Type: ApplicationFiled: July 19, 2006Publication date: November 23, 2006Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Jeffrey Way, Kin-Ming Lo
-
Patent number: 7115261Abstract: The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.Type: GrantFiled: February 11, 2000Date of Patent: October 3, 2006Assignees: The Scripps Research Institute, EMD Lexigen Research Center Corp.Inventors: Holger N. Lode, Ralph A. Reisfeld, David A. Cheresh, Stephen D. Gillies
-
Publication number: 20060194952Abstract: Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.Type: ApplicationFiled: May 9, 2006Publication date: August 31, 2006Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan, John Wesolowski
-
Patent number: 7091321Abstract: Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.Type: GrantFiled: February 9, 2001Date of Patent: August 15, 2006Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Christa Burger, Kin-Ming Lo
-
Patent number: 7067110Abstract: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.Type: GrantFiled: July 21, 2000Date of Patent: June 27, 2006Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin Ming Lo, John S. Wesolowski, Jr.
-
Publication number: 20060034836Abstract: Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.Type: ApplicationFiled: November 7, 2005Publication date: February 16, 2006Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Christa Burger, Kin-Ming Lo
-
Patent number: 6992174Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: GrantFiled: March 29, 2002Date of Patent: January 31, 2006Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Anita A. Hamilton
-
Patent number: 6969517Abstract: The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.Type: GrantFiled: May 3, 2002Date of Patent: November 29, 2005Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo, Susan X. Qian